Navigation Links
Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea

COLUMBIA, Md., Dec. 13 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation announced today that it has entered into a multi-year DHA and ARA license and supply agreement for infant formula with IlDong Foodis, an affiliated company of IlDong Pharmaceutical. Under the terms of the agreement, Martek will serve as the exclusive ARA supplier for all IlDong Foodis infant formula products in South Korea.

Martek manufactures nutritional oils that contain the long-chain polyunsaturated fatty acids DHA and ARA, both of which are naturally present in breast milk. Clinical studies have demonstrated benefits for infants receiving formula supplemented with DHA and ARA. Martek's proprietary blend of DHA and ARA, marketed under the brand names life'sDHA(TM) and life'sARA(TM), is currently used in over 90 percent of U.S. infant formulas. Additionally, infant formula containing life'sDHA and life'sARA has been consumed by over 25 million infants in over 70 countries worldwide.

"This new agreement is another important step in Martek's effort to expand its international presence in the infant formula market," said Brian Sparg, vice president of global nutrition for Martek. "Our partnership with IlDong Foodis further demonstrates that companies worldwide understand the importance of adding Martek's DHA and ARA to infant formula for infant health and development."

IlDong Foodis, an affiliated company of IlDong Pharmaceutical, sells infant formula, infant cereals, powdered beverages for adults and children, fruit juices and other food products. IlDong Pharmaceutical is a South Korean-based manufacturer and distributor of pharmaceuticals, as well as a manufacturer of raw ingredients such as probiotics.

DHA (docosahexaenoic acid) omega-3 is a long-chain omega-3 fatty acid that serves as a primary building block for the brain and the eyes and supports brain, eye and cardiovascular health throughout life. There is a large and growing body of scientific evidence demonstrating that people of all ages, from infants and mothers to aging adults, benefit from an adequate supply of DHA omega-3 in their diets. Scientific reviews have noted the importance of DHA omega-3 in proper brain and eye development and function, and there are numerous studies currently underway to investigate its role in decreasing the prevalence of certain neurological disorders and certain heart health disorders. ARA, a long-chain omega-6 fatty acid, is the principal omega-6 in the brain and abundant in other cells throughout the body. Like DHA, ARA is important for proper brain development in infants. It is also a precursor to a group of hormone-like substances called eicosanoids that play a role in immunity, blood clotting and other vital functions in the body.

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA(TM), a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2006 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.


Cassie France-Kelly

Public Relations

(443) 542-2116

Kyle Stults

Investor Relations

(410) 740-0081

SOURCE Martek Biosciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Martek to Announce Third Quarter 2007 Results on September 5, 2007
2. Martek to Present at Upcoming UBS Conference
3. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
4. Martek Announces Settlement of OmegaTech Milestone Litigation
5. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
6. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
7. Martek to Present at Upcoming ThinkEquity Partners Conference
8. Martek Announces Fourth Quarter and FY 2007 Financial Results
9. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
10. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
11. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... India , November 26, 2015 ... The Global Biobanking Market 2016 - 2020 report ... by maintaining integrity and quality in long-term samples, ... enabling long-term cost-effectiveness. Automation minimizes manual errors such ... the technical efficiency. Further, it plays a vital ...
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
Breaking Biology Technology:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Fingerprint Sensors - Technology and Patent Infringement Risk Analysis" ... --> --> Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
(Date:11/20/2015)... November 20, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Pereira , was recently interviewed on The RedChip ... on this weekend on Bloomberg Europe , Bloomberg ... --> NXTD ) ("NXT-ID" or the "Company"), ...
(Date:11/19/2015)... , Nov. 19, 2015  Based on its ... & Sullivan recognizes BIO-key with the 2015 Global Frost ... year, Frost & Sullivan presents this award to the ... catering to the needs of the market it serves. ... line meets and expands on customer base demands, the ...
Breaking Biology News(10 mins):